This is an exploratory study evaluating the combination of a MEK 1 and 2 inhibitor with chemotherapy in patients with advanced pancreatic cancers who have received and failed the two standard chemotherapy regiments. The gene discussed is MAP2K1; the disease is pancreatic neoplasm.